Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Johnson & Johnson

USAAdoptersAssignment FullData quality High

Key messagelimited AI Footprint

Johnson & Johnson has the use of artificial intelligence overseen by its board, trains employees widely and has audited procedures for information security, but publishes little on the review rules, limitations and test results of its AI applications. Lawsuits remain open over a navigation device for sinus procedures to which a former group subsidiary had added AI; no court has yet ruled on them.

Opportunities

  • Safetysolid

    Documented procedures exist for technical data and system protection: Item 1C with an incident response plan, a third-party risk programme, external maturity assessments and quarterly reports by the CISO to the RCS committee (S03), documented procedures for reporting vulnerabilities in IT and …

    Documented procedures exist for technical data and system protection: Item 1C with an incident response plan, a third-party risk programme, external maturity assessments and quarterly reports by the CISO to the RCS committee (S03), documented procedures for reporting vulnerabilities in IT and medical devices (S17, S18) and a training rate of 97% (S08). AI medical devices go through FDA clearance, for example the AI navigation software Monarch Quest (S20), but published validation results are missing. The TruDi case is open and of medium severity: after the then J&J subsidiary Acclarent added AI, unconfirmed FDA reports rose sharply, two lawsuits are pending and there is no finding (S22, S24, S25). Hence solid, not strong.

Risks

  • Responsibilitylimited

    The 2026 proxy statement documents AI-specific board responsibility: the board and its committees oversee the use of AI and receive regular updates, and the Science & Technology Committee lists AI as a risk area (S04).

    The 2026 proxy statement documents AI-specific board responsibility: the board and its committees oversee the use of AI and receive regular updates, and the Science & Technology Committee lists AI as a risk area (S04). What is missing, however, is an AI policy with operational content or a described approval, risk classification or review procedure published by the company and documented at grade A or B: the AI principles on jnj.com are undated and documented only as a general policy (C), the 2025 GenAI compliance guide is known by name only, and the central GenAI review body was dissolved in 2025 in favour of decentralised management (S01, S09, S11). Broad AI training is documented with figures (almost 120,000 completions, S08; a GenAI course as a prerequisite for use, S12); an external audit and an AI-specific complaints channel are missing.

  • Transparencylimited

    Transparency and explainability are stated as a principle, including documentation of how models are built, used and monitored (S01).

    Transparency and explainability are stated as a principle, including documentation of how models are built, used and monitored (S01). The 10-K names the use of AI and AI risks only in general terms (S02), and the company's web pages describe applications without limitations or performance data (S14, S19). Model or system cards, transparency reports, training data information and published limitations of the AI medical devices were not found (S20, S22). Hence limited, at the level of principles.

  • Risk area

    AI in medical devices that act directly on patients

  • Risk area

    AI in drug safety, clinical trials and regulatory documents

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
42searches
43pages and documents read
13primary documents
4controversies checked
5open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Johnson & JohnsonOverall rating: limited

Johnson & Johnson has its board oversee the use of AI, trains employees widely and has audited procedures for information security. A published AI policy and the limitations and test results of its AI medical devices are missing.

Safety

40 %
limitedsolidstrong

Audited procedures for information security, but no test results for AI products.

  • +CISO reports quarterly to a board committee Source ↗
  • +Vulnerability disclosure procedures for IT and medical devices Source ↗
  • –No published validation results for AI medical devices Source ↗
  • –More FDA reports after AI was added to TruDi, lawsuits pending Source ↗
All sources for this pillar (16)

Transparency

20 %
limitedsolidstrong

Transparency is a principle, but model information and AI product limitations are missing.

  • +Principles require documentation of how models are built and used Source ↗
  • +The 10-K discloses AI use and AI risks in general terms Source ↗
  • –No model or system cards and no transparency report
  • –No published limitations of the AI navigation Source ↗
All sources for this pillar (6)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Publish the AI policy and have it audited

Publish an AI policy with risk classes and approval procedures and have AI management externally audited.

2Safety
Disclose validation of AI medical devices

Publish validation results, error rates and post-market data for AI functions in medical devices.

3Transparency
Publish model cards and limits

Publish model and system cards with limitations and training data information for the main AI applications.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Johnson & Johnson is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
4 2 medium, 2 minor

No deduction for controversies.

Largest risk area
Injuries from AI navigation during procedures

According to Reuters, unconfirmed FDA reports rose sharply after the then subsidiary Acclarent added AI to the TruDi navigation system; two lawsuits are pending.

How thoroughly assessed
31 Evidence

13 primary documents read, 42 searches.

Read the full reasoning and all sources
Johnson & Johnson · Full reasoning

AI oversight at board level, but little information on testing of AI medical devices

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

Johnson & Johnson documents board oversight of AI and broad AI training, but publishes only general AI principles; risk classes, approval procedures and external audits are not disclosed.

What is documented
  • The board and its committees oversee the use of AI with regular updates; the Science & Technology Committee lists AI as a risk area1
  • In 2025 there were almost 120,000 completions of AI learning content; all employees receive basic AI training3
  • A compliance guide on generative AI was introduced in 20254
  • A GenAI course is a prerequisite for using generative AI tools8
  • The AI principles require human review, monitoring and bias testing6
The case against
Rules not disclosed
  • No published AI policy with risk classes and no approval procedure for purchased AI systems were found
  • No named person with overall responsibility for AI governance is identified
  • There is no external audit or certification of AI management and no AI-specific complaints channel
Decentralised management
  • According to the WSJ, the central body reviewing GenAI ideas was dissolved in 2025 and management delegated to the functions7 5
Sources for Responsibility (9)
  1. Johnson & Johnson (SEC EDGAR): Proxy Statement 2026 (DEF 14A) · 9 March 2026 · primary source
  2. Johnson & Johnson (SEC EDGAR): Proxy Statement 2025 (DEF 14A) · 12 March 2025 · primary source
  3. Johnson & Johnson: 2025 Health for Humanity Report (consolidated) · 1 June 2026 · primary source
  4. Johnson & Johnson: 2025 Health for Humanity Report – Accountability & Governance · 1 June 2026 · primary source
  5. CDO Magazine: How J&J Global Services Scales Enterprise AI Through Intelligent Operations and Governance · 9 February 2026 · secondary source
  6. Johnson & Johnson (jnj.com): Doing the Right Thing: Artificial Intelligence and Ethics · 3 November 2026 · secondary source
  7. The Wall Street Journal (reproduced via Dow Jones on itiger.com): Johnson & Johnson Pivots Its AI Strategy · 18 April 2025 · secondary source
  8. MIT Chief Data Officer and Information Quality (MIT CDOIQ): Q&A with Jim Swanson, Executive Vice President & Chief Information Officer, Johnson & Johnson · 5 June 2024 · secondary source
  9. Johnson & Johnson (jnj.com): Our Position on Data Privacy · 1 May 2023 · secondary source

2 · Safety

solidWeight 40%

Johnson & Johnson documents procedures for data and system protection and channels for reporting vulnerabilities, but validation results for its AI medical devices are missing and the TruDi case is open.

What is documented
  • Item 1C describes an incident response plan, a third-party risk programme, external maturity assessments and quarterly CISO reports7
  • Vulnerability disclosure procedures for IT and medical devices exist, with acknowledgement within 3 and 10 working days13 14
  • The information security training rate was 97%3
  • The AI-supported navigation software Monarch Quest received FDA 510(k) clearance in 20251
The case against
Missing evidence of testing
  • Validation results, error rates and post-market data for the AI medical devices are not published1
  • A named framework, results of the external maturity assessments and information on protecting AI models are missing
Incidents and lawsuits
  • According to Reuters, unconfirmed FDA reports rose from 8 to over 100 after AI was added to TruDi; two lawsuits are pending4 5 6
  • A settlement over the Skin360 AI skin analysis concerns the former consumer subsidiary, now Kenvue15 16
Sources for Safety (16)
  1. MedPath: FDA Clears J&J's AI-Enhanced Monarch Robot for Improved Lung Cancer Diagnosis · 14 March 2025 · secondary source
  2. Johnson & Johnson (jnj.com): Doing the Right Thing: Artificial Intelligence and Ethics · 3 November 2026 · secondary source
  3. Johnson & Johnson: 2025 Health for Humanity Report (consolidated) · 1 June 2026 · primary source
  4. Aaj English TV (reproduced via Reuters): AI-enhanced medical device faces scrutiny after injury reports · 9 February 2026 · secondary source
  5. AI Incident Database: Incident 1436: AI-Enabled TruDi Navigation System Was Alleged to Have Contributed to Patient's Stroke During June 2022 Sinus Procedure · 28 March 2026 · secondary source
  6. AI Incident Database: Incident 1528: TruDi-associated stroke during sinuplasty in May 2023 · 9 June 2026 · secondary source
  7. Board Cybersecurity (reproduced from SEC mandatory disclosure): Johnson & Johnson 10-K Item 1C. Cybersecurity – 2026-02-11 · 11 February 2026 · primary source
  8. Johnson & Johnson (SEC EDGAR): Form 10-K for the fiscal year ended December 28, 2025 · 11 February 2026 · primary source
  9. Johnson & Johnson: 2025 Health for Humanity Report – Accountability & Governance · 1 June 2026 · primary source
  10. Johnson & Johnson (jnj.com): Our Position on Information Security · 1 March 2023 · secondary source
  11. Infosecurity Magazine: IBM Patient Data Breach Hits Johnson & Johnson · 2 August 2023 · secondary source
  12. Kirkland & Ellis (reproduced via Am Law Litigation Daily): Litigator of the Week Runners-Up and Shout Outs · 25 September 2026 · secondary source
  13. Johnson & Johnson (jnj.com): Coordinated Vulnerability Disclosure Statement (Version 2.0) · 6 July 2026 · primary source
  14. Johnson & Johnson MedTech: Product Security (productsecurity.jnj.com) · 3 November 2026 · primary source
  15. Settlement Administrator (court-ordered notice): Skin360 Settlement Notice · 3 November 2026 · primary source
  16. ID Tech Wire: Kenvue Agrees to $4.7M BIPA Settlement Over Neutrogena Skin-Scanning App · 24 February 2026 · secondary source

3 · Transparency

limitedWeight 20%

Johnson & Johnson names transparency and explainability as a principle, but publishes neither model cards nor limitations or performance data for its AI applications.

What is documented
  • The AI principles require explainable models or, where that is not possible, proactive monitoring4
  • The 10-K discloses the use of machine learning and AI and the risks of unintended consequences1
  • Company pages and the report name AI applications in trials, pharmacovigilance and sales2 3
The case against
Missing disclosure
  • No model or system cards, AI transparency report or training data information were found
  • Limitations and error rates of AI functions in medical devices such as Monarch are not documented5
  • There are no rules for labelling AI-generated content for patients or professionals
Sources for Transparency (6)
  1. Johnson & Johnson (SEC EDGAR): Form 10-K for the fiscal year ended December 28, 2025 · 11 February 2026 · primary source
  2. Johnson & Johnson: 2025 Health for Humanity Report (consolidated) · 1 June 2026 · primary source
  3. Johnson & Johnson (jnj.com): Artificial Intelligence: Advancing Healthcare from New Jersey to the World · 4 September 2026 · secondary source
  4. Johnson & Johnson (jnj.com): Doing the Right Thing: Artificial Intelligence and Ethics · 3 November 2026 · secondary source
  5. MedPath: FDA Clears J&J's AI-Enhanced Monarch Robot for Improved Lung Cancer Diagnosis · 14 March 2025 · secondary source
  6. Johnson & Johnson MedTech (press release): Johnson & Johnson launches the Polyphonic AI Fund for Surgery to advance data-driven healthcare · 25 June 2025 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: the TruDi case is pending without a judgment or authority decision, the Skin360 settlement concerns Kenvue, and the ChemImage judgment concerns a contract dispute.

5 · Controversies (4)

6 · What remains open

  • Published AI policy with risk classification and approval procedures
  • External audit or certification of AI management
  • Validation results, limitations and post-market data for the AI medical devices
  • Statement on the TruDi case and any liability or indemnity rules from the Acclarent sale
  • Items 1C and 3 of the 10-K in the original, which could not be read on retrieval

7 · How it was assessed

Cut-off date: 3 November 2026 · 42 searches, 43 fetches.

Primary documents read (13)
  • Form 10-K FY2025 (Item 1, Item 1A, beginning of Item 1C)
  • Form 10-K FY2025 Item 1C (reproduced via board-cybersecurity.com)
  • Proxy Statements 2026, 2025 and 2024
  • Form 8-K Annual General Meeting 2026
  • 2025 Health for Humanity Report (consolidated, including continuation) and chapter Accountability & Governance
  • Doing the Right Thing: Artificial Intelligence and Ethics
  • Our Position on Data Privacy
  • Our Position on Information Security
  • Coordinated Vulnerability Disclosure Statement
  • Product Security (productsecurity.jnj.com)
  • Press release: Polyphonic AI Fund
  • FDA Recall Z-0051-2025
  • Skin360 Settlement Notice

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next